Quote:
Originally Posted by spiderplant
Yes, but in this case the protection from one dose is a lot lower than that from two, which wasn't the case in the original trials. It would explain the sudden rush to give second doses to the over-50s.
"This suggests a single shot offers 35 per cent less protection against B.1.617.2 compared with B.1.1.7, according to Financial Times analysis"
Though not as effective as the leading two-dose vaccines. J&J are now running a two-dose trial:
https://www.nytimes.com/interactive/...acker.html#jnj |
Again, point missed. From Andrews post:-
New UK government research suggests two doses of a Covid-19 vaccine are needed to provide strong protection against symptomatic infection from the coronavirus variant first identified in India, according to two people briefed on the preliminary data.
. . which has always been the case (apart from J&J)